your market intelligence analyst
Search Results
5 results
Your search is now limited to «Tuberculosis» expert search.
European Respiratory Journal 10/22/2020 03:15
The persisting worldwide burden of tuberculosis (TB) is worrisome. In 2018, an estimated 10 million individuals developed TB and 1.45 million infected individuals died [1]. The increase in drug resistance is an important point of concern. Resistance can be acquired by inappropriate drug management, noncompliance and insufficient drug exposure [2, 3]. The last is frequently described for the first-line TB drugs rifampicin and isoniazid due to large interindividual pharmacokinetic variability [3]. Therapeutic drug monitoring (TDM) can be used to verify drug exposure and adjust individual drug dosages if needed [4].

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities


Strategic Scenarios